Published in:Johns Hopkins Carey Business School Research Paper ; No. 21-10
Extent:
1 Online-Ressource (21 p)
Language:
English
DOI:
10.2139/ssrn.3386685
Identifier:
Origination:
Footnote:
Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments May 2, 2019 erstellt
Description:
We use Swedish data on 330,000 consumer choices of medically equivalent drugs to study the zero-price effect first documented by Shampanier et al. (2007) in experimental settings. The Swedish benefit scheme implies that, during a given month, all consumers face the same price-differences between generic substitutes and that about a fifth of the consumers pay a zero price if they choose the cheapest substitute. Using both regression discontinuity designs and discrete choice models, we find no evidence for the zero-price effect in our study